We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review.
- Authors
Han, Zeping; Liang, Jiening; Li, Yuguang; He, Jinhua
- Abstract
B-cell lymphoma 2 (Bcl-2) is a regulator protein involved in apoptosis. In the past few decades, this protein has been demonstrated to have high efficacy in cancer therapy, and several approaches targeting Bcl-2 have been tested clinically (e.g., oblimersen, ABT-737, ABT-263, obatoclax mesylate, and AT-101). This review reports potential Bcl-2 inhibitors according to current information on their underlying mechanism and the results of clinical trials. In addition, the function and mechanisms of other potentially valuable Bcl-2 inhibitors that did not show efficacy in clinical studies are also discussed. This summary of the development of Bcl-2 inhibitors provides worthwhile viewpoints on the use of biomedical approaches in future cancer therapy.
- Subjects
ANTINEOPLASTIC agents; APOPTOSIS; CELL lines; CHALONES; CLINICAL trials; DNA; GENE expression; NUCLEOTIDES; PROTEINS; TUMORS; INVESTIGATIONAL drugs; PHARMACODYNAMICS
- Publication
BioMed Research International, 2019, p1
- ISSN
2314-6133
- Publication type
Article
- DOI
10.1155/2019/1212369